Long‐term disease control and safety with the anti‐CCR4 antibody mogamulizumab: Post‐hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T‐cell lymphoma. Issue 8 (28th June 2022) - Bagot, Martine; Dalle, Stéphane; Sokol, Lubomir; Tsianakas, Athansios; Musiek, Amy; Ortiz‐Romero, Pablo L.; Poligone, Brian; Duvic, Madeleine; Elmets, Craig; Leoni, Mollie; Dwyer, Karen; Ito, Takahiro; et al.